LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

Similar documents
Investigator Site File Index (CTIMP)

Investigator Site File Index (Medical Devices)

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Index of Standard Operating Procedures for all research Sponsored by the UHL

Louise Brook Clinical Trials Quality Monitor. Date

Research Study Close-down and Archiving Procedures

Index of Standard Operating Procedures for all research Sponsored by the UHL

Standard Operating Procedure

R&D Administration Manager. Research and Development. Research and Development

RESEARCH AUDIT Standard Operating Procedure

Once notified of the end of trial, a Research Manager, on behalf of the Sponsor, will contact the CI to arrange a close down monitoring visit.

STANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site

Trial Master File. SOP No. SOP 7

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.

Conducting Clinical Trials of Investigational Medicinal Products

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

Site Initiation and Activation

Document Title: Site Recruitment and Initiation for Papworth Sponsored Studies

Standard Operating Procedure for Archiving

Study Files and Filing

Standard Operating Procedure. GCP Auditing of Research Studies

End of Study Notification, Close-Out and Reporting Sponsored Research. Noclor/Spon/S11/01. SOP Reference ID:

Standard Operating Procedures (SOP) Research and Development Office

SPONSOR INVESTIGATIONAL MEDICINAL PRODUCT (IMP) MANAGEMENT

Investigational Medicinal Product (IMP) Management Standard Operating Procedure

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

OFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out

Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility

Date: 23 rd December 2014 Version 5 Page 1 of 8 STANDARD OPERATING PROCEDURE FOR TRIAL INITIATION AND SITE SET UP (NWORTH 3.03)

Standard Operating Procedure. GCP Auditing of Research Studies. SOP effective: 23rd January 2018 Review date: 23rd January 2020

Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility

IMP Management and Accountability

ISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual

Trial Committees SOP Number: 47 Version Number: 2.0 Effective Date: 01/02/2017 Review Date: 01/02/2019

ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL

R&D Administration Manager. Research and Development. Research and Development. NHS Staff Trust-Wide THIS IS A CONTROLLED DOCUMENT

STANDARD OPERATING PROCEDURE

Marie-Claire Good, RG and GCP Manager James Rickard, Deputy Chief Pharmacist Technical Services Cheryl Lawrence, Senior Research Pharmacist

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

STUDY CLOSURE AND ARCHIVING

Standard Operating Procedure. Vendor Management

Document Number: SOP/RAD/SEHSCT/003 Page 1 of 9 Version 2.0

Standard Operating Procedure

STANDARD OPERATING PROCEDURE

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:

Standard Operating Procedure. SOP effective: 19 February 2016 Review date: 19 February 2018

Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials

STANDARD OPERATING PROCEDURE

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight

STANDARD OPERATING PROCEDURE SOP 725 CAPACITY, CAPABILITY AND RISK ASSESSMENT OF TRIALS HOSTED BY NNUH

Document Title: Handling of drug alerts and recalls of IMPs

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust

STUDY REQUEST FORM AND TRAQ DSS FORM

Date: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

RDSOP28 Randomisation and Unblinding in Clinical Trials of an Investigational Medicinal Product (CTIMPs)

UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH SUPPORT OFFICE

STANDARD OPERATING PROCEDURE

ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Regulatory Binder: Set-up and Maintenance

Inspections: an academic perspective

STANDARD OPERATING PROCEDURE

Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs

Investigator s Responsibility

Standard Operating Procedure (SOP) Research and Development Office

Sally Burtles, Director of Research Services & Business Development

and Study Initiation

and Study Initiation

Standard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations

Writing a Protocol to Good Clinical Practice (GCP)

Joint Research Office of Doncaster & Bassetlaw

Standard Operating Procedure. SOP effective: 23 July 2015 Review date: 23 July 2017

STANDARD OPERATING PROCEDURE

STANDARD OPERATING PROCEDURE SOP 320. Developing a Research Protocol

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

NIS Considerations - Bulgaria

Preparing for Close-Out of Studies and Sites

Use of computerised equipment, software and systems in clinical research

Writing a Protocol for CTIMPs

Standard Operating Procedure. SOP effective: 21 December 2017 Review date: 21 December 2019

Aldrey Oliveira June 2nd 2016 Rio de Janeiro - Brazil

COMBINED RISK ASSESSMENT

Maintaining the blind for clinical trials in Pharmacy

Trial oversight SOP for HEY-sponsored CTIMPs

Compliance Program Guidance Manuals (CPGMs) -1-

NHS Tayside Effective Date: 24/7/2009

Marie-Claire Rickard, RG and GCP Manager Cheryl Lawrence, Senior Research Pharmacist Damien Kelly, Barts Pharmacy Site and Clinical Trials Lead

Storage of Clinical Trials Materials and Investigational Medicinal Products

Confirming Research Study Capacity and Capability

Details: Approval: Distribution & Storage:

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

Effective Date: 1 May 2017

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

Transcription:

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough University Effective Date: October 2015 1.0 Introduction This Standard Operating Procedure (SOP) describes the procedures for reporting and documentation requirements for the closure of research sponsored by Loughborough University (LU). The document covers closure as defined in the protocol, along with early termination for safety, ethical or logistical reasons and closure of individual sites in Multi-centre studies. The outcome is that the Sponsor is able to confirm study closure. 2.0 Scope This SOP applies to all research sponsored by Loughborough University. 3.0 Procedure Trial closure should be performed as defined in the study protocol and in accordance with regulatory requirements and Good Clinical Practice guidelines (GCP). Any planned changes to the end of study should be submitted as a Substantial Amendment to the REC, appropriate regulatory bodies, and the NHS Trust R&D in accordance with SOP -1026 LU Sponsor Approval Process for Amendments. The objective of trial closure is to ensure that: The rights and wellbeing of all participants have been protected All essential documents have been stored appropriately in the Trial Master File (TMF) and Investigator Site Files (ISF) Page 1 of 15

The correct approved version of the protocol was used and adhered to Any SAEs (Serious Adverse Event), and SUSARs (Suspected Unexpected Serious Adverse Reaction) have been reported appropriately Source Data Verification (SDV) has been undertaken Monitoring has been performed as described in the study monitoring plan All contractual requirements have been met Any outstanding queries between the Sponsor and sites are resolved A study close-out report is produced Plans for close down should be included in the monitoring plan and discussed during the Sponsor Risk Assessment and Approval Process (Appendix 1). Archiving is covered in the Archiving SOP-1032 LU Archiving of Essential Documents. 3.1 Planned closure It is expected that the definition of planned study closure will be outlined in the study protocol. The end of study would usually be described as the last visit of the last patient or the final follow-up completion and data collection. Plans for closing the study should be discussed during the Sponsor Risk Assessment and Approval Process, and included in the monitoring plan. Final analysis of the locked database should occur after a study close down report has been completed. In cases of unblinding for randomised studies, written approval will be required. It is the responsibility of the Sponsor to ensure that study closure tracking and study end dates are maintained on the database. The aim is to support the production of an accurate overview and reporting of research activity sponsored by LU. It is the responsibility of the Chief Investigator to discuss study closure with the Sponsor and to complete relevant required documentation. The Sponsor will ensure that the regulatory authorities and REC receive completed documentation within 90 days in accordance with required timelines. Where required, a study close down visit will be performed. The site close down report (Appendix 2) and site close down visit logs (Appendix 3) must be completed and appended to the monitoring reports / monitoring plan. Database lock, validation and cleaning, must be done in accordance with SOP -1036 LU Data Management Process. 3.2 Premature Termination / Early Closure As Sponsor LU has a legal responsibility to notify the Research Ethics Committee (REC) as relevant that a study has terminated early at a site within 15 days of the termination, irrelevant of reason. It may also be necessary to notify the following: Page 2 of 15

Trial Management Group / Data Safety Monitoring Committee (where they have not been involved in the decision) Funding body / study finance staff All site investigators for multi centre studies Research can be terminated prior to the planned closure date or event because of: a. b. c. d. e. Adverse Events Slow recruitment Sponsor decision Investigator decision Regulatory decision It is essential that the CI discuss the process with the Sponsor to ensure that appropriate documentation is completed and submitted within the required timelines. 3.2.1 Multi-centre studies Closure of multi-centres must be documented and retained in the Investigator Site Files (ISF) and within the site section of the Trial Master File (TMF). Confirmation of closure must include the justification of the closure, the number of participants still receiving treatment and the proposed management of those participants where appropriate. A letter thanking the site for their contribution with an overall summary of the participants must be sent by the CI. The correspondence must include a reminder that the PI will be required to comply with any future audits or inspections of the closed study. There must be an agreed plan to resolve any financial balances, and information about the publication process. The expectation will be that archiving of site study documentation be managed by the individual site. This will be discussed at the initial set up of the study along with the process to be used, and individuals responsible for close down of individual sites. 3.3 Final Report A report of the study findings, negative and / or positive must be produced within one year of the closure date. LU as Sponsor will track this date using the database and will remind the investigator at least 30 days prior to the due date. 4.0 Archiving Essential Documents must be archived in accordance with the Archiving SOP 1032 LU. Details of what documents are regarded as essential are detailed in the SOP 1015 LU. Page 3 of 15

5.0 Responsibilities Responsibility 1 Chief Investigator (CI) in collaboration with Sponsor Undertaken by CI & Sponsor Activity Determine whether the Study: Is due to conclude as described in the study protocol; OR Requires an extension to the end date; OR Is to terminate early, and why. 2 CI CI / PI Discuss with Sponsor regarding study conclusion or extension requirement. Complete required documentation. 3 Sponsor Research Governance Officer or their delegate Maintain the relevant database/s with the end date and study status related to closure or extension based on information from the CI and set reminders for final reports 4 Sponsor / CI CI Inform the regulatory authorities and the REC, and all other relevant parties as necessary copying in the Sponsor to all correspondence. 5 Sponsor Research Governance Officer or their delegate 6 Sponsor/CI Research Governance Officer or their delegate /CI 6.0 Monitoring and Audit Criteria Ensure that all relevant parties are informed within the required timelines. Finalise the study files ensuring all necessary documents are present in TMFs / ISFs and ensuring all end of study procedures are completed. Key Performance Indicator All research sponsored by LU has appropriate study close down procedures in place. Method of Assessment Included in the monitoring / audit programme. Frequency Random audits / monitoring conducted on 10% of research activity. Lead Research Governance Officer or their delegate This table is used to track the development and approval of the document and any changes made on revised / reviewed versions Author / Lead Officer: DEVELOPMENT AND APPROVAL RECORD FOR THIS DOCUMENT Jackie Green Job Title: Research Governance Officer Page 4 of 15

Approved by: Ethics Committee Date Approved: 23/10/15 REVIEW RECORD Date Issue Number Reviewed By Description Of Changes (If Any) DISTRIBUTION RECORD: Date Name Dept Received Page 5 of 15

Appendix 1 Sponsor End of Study / Close-down Proforma Study Title (in full): Reference No: Has an appropriate public database been identified for registration of the study? Is the end of study defined in the Protocol? Are the plans for archiving study documentation from all sites clear? Is there adequate funding available for archiving for all sites or centrally? Is there a named individual responsible for study close down at each site? Has the individual responsible for authoring the end of trial reports been identified? Has the individual responsible for ensuring publication been identified? Has individual responsible for database lock at each site been identified? Has appropriate electronic storage been identified at each site or centrally? Has study close out been included in the Monitoring Plan? Yes No In progress Date Completed Page 6 of 15

Appendix 2 LU Site Close Down Report Site Information Site: Study title: Study number: Centre name: Investigator name: Date of visit: List of site and monitoring personnel in attendance Name Position Study Status Planned patient number Number of patients randomised Number of patients completed Number of patients withdrawn Number of patients lost to follow up Comments: 1. Protocol Items Discussed/verified Yes No Version/comment Is the current approved protocol on file? Is the protocol signed and dated? Are superseded protocols on file? Is there a protocol deviation log on file? Have protocol deviations been reported/reviewed by PI? Page 7 of 15

2. Ethics Items discussed/verified Yes No Comments Are all original applications/submissions/approvals on file? Are all substantial amendments complete and on file? Are all non substantial amendments complete and on file? Ethics correspondence on file? Notification of trial completion on file? 3. Competent Authority Items Discussed/verified Yes No N/A Comments Are all original applications/submissions/approvals on file? Is there CTA acknowledgement of amendment letter/s? Notification of trial completion on file? 4. R&D Are all original applications/submissions/approvals on file? Are all substantial amendment/s complete and on file? Are all non substantial amendment/s complete and on file? Notification of trial completion on file? R&D Correspondence on file? Page 8 of 15

5. Investigator Site Personnel Is the delegation of authority and signature log updated to reflect end of study Confirm that all CVs/GCP/training records are up to date and on file 6. Standard Operating Procedures Is the delegation of authority and signature log updated to reflect end of study Confirm that all CVs/GCP/training records are up to date and on file 7. Study Documentation Items Discussed/verified Yes No Versions/Comments Is the current approved patient documentation on file? Are all superseded patient documents on file? Are previous versions of study documentation marked as superseded? Is there a copy of the current Case Report Form on file? Are all superseded Case Report Forms on file? 8. Subject Documentation Is there a current screening log template on file? Is the Subject Screening log complete? Is there a current Enrolment Log template on file? Is the Enrolment Log complete, including an outcome for each subject? Page 9 of 15

9. Randomisation Items Discussed/verified Yes No N/A Comments Is there documentation of the Randomization Process on file? Where is the Master Randomization List held? Evidence of correct blinding as per study protocol? 10. Informed Consent Are all consent forms present and correctly completed? Has 100% consent audit been undertaken and documentation of the audit on file? Is informed consent process properly documented in the medical/trial records 11. Safety Reporting/Pharmacovigilance Items discussed/verified Yes No N/A Comments Are SAE reporting Guidelines/SOP and Pharmacovigilance/Governance contact on file? Is there a Current SAE form Template on file? Are SAE reports and associated acknowledgement correspondence from Sponsor/R&D on file? Are SUSAR reporting guidelines on file? Are SUSAR reports and associated acknowledgement correspondence from Sponsor/ R&D on file? Are there signed and dated annual Development Safety Update Report(s) on file? Page 10 of 15

12. Monitoring Is study initiation and subsequent monitoring visit documentation on file? Is the monitoring log complete and on file? Comments/findings 13. Clinical Laboratory/Specimen Collections Items Discussed/verified Yes No N/A Have central Labs been used? Are the current and previous Central Lab accreditations on file? Is Central Lab normal reference ranges on file? Are there signed and dated copies of CVs of Heads of departments? Have Local Labs been used? Are the Local Laboratory current and previous accreditation certificates on file? Local Lab normal reference ranges Are sampling and sample handling procedures documented/is there a lab manual on file? Are specimen results reviewed and signed and dated by PI? Are specimen results that are out of range marked as clinically significant or not clinically significant? Are sample logs/records complete and on file? Is there on going storage of samples for future research? If yes; Are storage conditions monitored and recorded? Have all samples been analysed and destroyed as per protocol? Have the retained samples been sent to Central Labs or destroyed? (Unless permission to keep samples for future research) Has all supplied equipment been returned? Page 11 of 15

14. Pharmacy Items Discussed/verified Yes No N/A Comments Are Pharmacy Staff GCP and CVs up to date and on file? Is the Delegation of Authority and signature log updated to reflect end of study? Are instructions in place with regards to handling trial medication and trial related materials? Dispensing procedure Randomization/resupply/returns and destruction? Is there a Pharmacy approved Prescription template on file? Records of drug dispensing on file and has the drug been correctly dispensed with all completed prescriptions on file? Have drug accountability records been completed? Have any drug excursions been recorded? Have any drug been quarantined? Are all required GMP, certificate of analysis and QP release documents on file? 15. Financial/Legal agreements Items Discussed/verified Yes No N/A Comments Are all completed documents relating to contracts, finance, funding, indemnity and sponsorship on file? 16. Study Related Supplies Items Discussed/verified Yes No N/A Are all study related supplies documents completed and on file? Are all maintenance and calibration records completed and on file? Page 12 of 15

17. Annual/Final Reports Items Discussed/verified Yes No Are annual progress and where applicable safety reports to the Ethics Committee on file? Are R&D confirmations of annual report receipt on file? 18. Publication Items Discussed/verified Yes No Are copies of all study analysis publications on file? 19. Correspondence Items Discussed/verified Yes No Is all study related correspondence on file? Comments/Finding 20. Source Data Verification Are all CRFs complete and all data queries resolved? Has all patient identifiable data been removed? Where required, has a do not destroy dated sticker been added to the patient notes? 21. Data Protection Are computer records and files containing identifiable data stored on a remote and secure server? Is the emergency recovery procedure for retrieving data available? Is access to electronic study records and files password protected? Are electronic data files for analysis anonymised? Is there provision in place for suitable archiving? Page 13 of 15

If yes are details logged with the R&D office? 22. Other if not covered above Items Discussed/verified Yes No Category Additional Comments/Overview Confirmation by Sponsor/Sponsors delegate that the study is ready for closure. Name (Print).. Signature.. Role.. Page 14 of 15

LU Site Closedown Visit Log Date of Visit: LU Sponsor Reference: Chief Investigator: Principle Investigator: Study Title: Site : Name Role in study Signature Page 15 of 15